Safety of bronchial thermoplasty in patients with severe refractory asthma
Background: Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 years to evaluate long-term safety of this procedure. Objectives: To assess long-term sa...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797079037966811136 |
|---|---|
| author | Pavord, I Thomson, N Niven, R Corris, P Chung, K Cox, G Armstrong, B Shargill, N Laviolette, M |
| author_facet | Pavord, I Thomson, N Niven, R Corris, P Chung, K Cox, G Armstrong, B Shargill, N Laviolette, M |
| author_sort | Pavord, I |
| collection | OXFORD |
| description | Background: Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 years to evaluate long-term safety of this procedure. Objectives: To assess long-term safety of BT for 5 years. Methods: Patients with asthma aged 18 to 65 years requiring high-dose inhaled corticosteroids (ICSs) (>750 μg/d of fluticasone propionate or equivalent) and long-acting β2-agonists (LABAs) (at least 100 μg/d of salmeterol or equivalent), with or without oral prednisone (≤30 mg/d), leukotriene modifiers, theophylline, or other asthma controller medications were enrolled in the Research in Severe Asthma (RISA) Trial. Patients had a prebronchodilator forced expiratory volume in 1 second of 50% or more of predicted, demonstrated methacholine airway hyperresponsiveness, had uncontrolled symptoms despite taking maintenance medication, abstained from smoking for 1 year or greater, and had a smoking history of less than 10 pack-years. Results: Fourteen patients (of the 15 who received active treatment in the RISA Trial) participated in the long-term follow-up study for 5 years. The rate of respiratory adverse events (AEs per patient per year) was 1.4, 2.4, 1.7, and 2.4, respectively, in years 2 to 5 after BT. There was a decrease in hospitalizations and emergency department visits for respiratory symptoms in each of years 1, 2, 3, 4, and 5 compared with the year before BT treatment. Measures of lung function showed no deterioration for 5 years. Conclusion: Our findings suggest that BT is safe for 5 years after BT in patients with severe refractory asthma. Trial Registration: clinicaltrials.gov Identifier: NCT00401986. © 2013 American College of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved. |
| first_indexed | 2024-03-07T00:39:55Z |
| format | Journal article |
| id | oxford-uuid:82b266b8-a9e6-4d4a-a30b-93a853533a58 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:39:55Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:82b266b8-a9e6-4d4a-a30b-93a853533a582022-03-26T21:39:10ZSafety of bronchial thermoplasty in patients with severe refractory asthmaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:82b266b8-a9e6-4d4a-a30b-93a853533a58EnglishSymplectic Elements at Oxford2013Pavord, IThomson, NNiven, RCorris, PChung, KCox, GArmstrong, BShargill, NLaviolette, MBackground: Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 years to evaluate long-term safety of this procedure. Objectives: To assess long-term safety of BT for 5 years. Methods: Patients with asthma aged 18 to 65 years requiring high-dose inhaled corticosteroids (ICSs) (>750 μg/d of fluticasone propionate or equivalent) and long-acting β2-agonists (LABAs) (at least 100 μg/d of salmeterol or equivalent), with or without oral prednisone (≤30 mg/d), leukotriene modifiers, theophylline, or other asthma controller medications were enrolled in the Research in Severe Asthma (RISA) Trial. Patients had a prebronchodilator forced expiratory volume in 1 second of 50% or more of predicted, demonstrated methacholine airway hyperresponsiveness, had uncontrolled symptoms despite taking maintenance medication, abstained from smoking for 1 year or greater, and had a smoking history of less than 10 pack-years. Results: Fourteen patients (of the 15 who received active treatment in the RISA Trial) participated in the long-term follow-up study for 5 years. The rate of respiratory adverse events (AEs per patient per year) was 1.4, 2.4, 1.7, and 2.4, respectively, in years 2 to 5 after BT. There was a decrease in hospitalizations and emergency department visits for respiratory symptoms in each of years 1, 2, 3, 4, and 5 compared with the year before BT treatment. Measures of lung function showed no deterioration for 5 years. Conclusion: Our findings suggest that BT is safe for 5 years after BT in patients with severe refractory asthma. Trial Registration: clinicaltrials.gov Identifier: NCT00401986. © 2013 American College of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved. |
| spellingShingle | Pavord, I Thomson, N Niven, R Corris, P Chung, K Cox, G Armstrong, B Shargill, N Laviolette, M Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title_full | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title_fullStr | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title_full_unstemmed | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title_short | Safety of bronchial thermoplasty in patients with severe refractory asthma |
| title_sort | safety of bronchial thermoplasty in patients with severe refractory asthma |
| work_keys_str_mv | AT pavordi safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT thomsonn safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT nivenr safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT corrisp safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT chungk safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT coxg safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT armstrongb safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT shargilln safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma AT laviolettem safetyofbronchialthermoplastyinpatientswithsevererefractoryasthma |